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Abstract: Expression of CCR2, CXCR3 and CCR4 on CD4
+ T or CD8
+ T cells in blood and cerebrospinal ﬂ  uid (CSF) for 
multiple sclerosis (MS) was measured by 3-color ﬂ  ow cytometry, and compared to blood from healthy controls and CSF 
from patients with other inﬂ  ammatory neurological diseases (INDs). CD4
+CXCR3
+/CD4
+CCR4
+ ratio (representing Th1/
Th2 balance) was higher in both CSF and blood of MS patients than those of IND patients or healthy controls. Percentage 
of CCR2-positive T cells was signiﬁ  cantly higher in CSF from MS patients. Increased CCR2 expression on T cells in CSF 
and Th1/Th2 imbalance may reﬂ  ect the pathological processes involved in MS.
Keywords: multiple sclerosis, CCR2, CXCR3, CCR4, chemokine receptor, chemokine
Introduction
Multiple sclerosis (MS) is a chronic and progressive inﬂ  ammatory immune-mediated demyelinating 
disease. Recruitment of peripheral blood mononuclear cells into the central nervous system (CNS) plays 
a crucial role in the pathogenesis of this condition. Chemokines are low molecular weight cytokines 
produced in inﬂ  amed tissue, mediating the recruitment of speciﬁ  c leukocyte populations expressing 
chemokine receptors. Recent studies have shown that T cells expressing CCR5 and CXCR3 can be 
detected within perivascular lesions of brains with MS [Simpson et al. 1998; Balashov et al. 1999; 
Sorensen et al. 1999], and T cells expressing these receptors are increased in cerebrospinal ﬂ  uid (CSF) 
compared with peripheral blood [Kivisakk et al. 2002; Sorensen et al. 1999, 2002; Teleshova et al. 
2002]. Increased expression of CXCR3 on CD4
+ T cells in peripheral blood from MS patients compared 
to those of healthy individuals has also been reported [Nakajima et al. 2004a]. Since such chemokine 
receptors are preferentially expressed on Th1 cells, these cells are considered critical in the pathogen-
esis of MS. In contrast, expression of CCR4 and CCR3 (Th2-type receptors) on CD4
+ T cells is sig-
niﬁ  cantly decreased in the blood of MS patients at the time of relapse compared to healthy controls, 
and CCR4 expression is signiﬁ  cantly decreased in CSF CD4
+ T cells compared to peripheral blood 
CD4
+ T cells [Misu et al. 2001]. These ﬁ  ndings suggest that Th2 response is suppressed in the acute 
phase of MS. Th1/Th2 balance may thus play an important role in this relapsing-remitting disorder 
[Misu et al. 2001; Nakajima et al. 2004a].
In experimental autoimmune encephalomyelitis (EAE), CCL2 and CCR2, the main receptor for CCL2, 
are expressed on astrocytes, macrophages and T cells in CNS lesions during the acute phase [Jee et al. 2002]. 
CCR2-knockout mice are also resistant to EAE [Fife et al. 2000; Izikson et al. 2000]. These ﬁ  ndings suggest 
that CCR2 and CCL2 are key susceptibility factors in EAE. Unexpectedly, CCL2 concentrations in CSF from 
MS patients after relapse are reduced when concentrations of other inﬂ  ammatory chemokines such as CCL1, 
CCL5 and CXCL10 are increased [Bartosik-Psujek and Stelmasiak, 2005; Mahad et al. 2002; Nakajima et al. 
2004a; Sorensen et al. 1999, 2001]. Since CCL2 has been shown to induce Th2 reactions [Gu et al. 2000; 
Nakajima et al. 2001], CCL2 production may be suppressed in the Th1-predominant immunological conditions 
of active MS. However, both CCR2 and CCL2 are abundantly detected in plaque lesions from MS patients 
[Mahad and Randsohoff, 2003; McManus et al. 1998]. Multiple compensatory mechanisms, particularly 464
Nakajima et al
Biomarker Insights 2007:2
concerned with CCL2-CCR2, appear to exist in the 
pathogenesis of MS.
The present study examined expressions of 
CXCR3, CCR4 and CCR2 on CD4
+ T and CD8
+ T 
cells in blood and CSF from relapsing-remitting MS 
patients and CSF from patients with other inﬂ  am-
matory neurological diseases (INDs). Comparing 
these groups, we evaluated speciﬁ  c T-cell popula-
tions trafﬁ  cking to the MS lesion. The results indicate 
that CCR2 upregulation in CSF occurs in MS.
Materials and Methods
Subjects
Paired blood and CSF samples were obtained from 
10 patients with relapsing-remitting MS during the 
relapse phase (8 women, 2 men; mean (±SD) age, 
44 ± 9 years (range, 20–56 years); mean disease 
duration 6 ± 5 years (range, 0.5–13 years); mean 
expanded disability status scale (EDSS) [Kurtzke 
et al. 1983] 3 ± 1.5 (range, 1.5–5.5)) (Table 1). All 
patients included in this study displayed deﬁ  nite 
MS, according to McDonald criteria [McDonald 
et al. 2001]. Samples were obtained from these 
patients before administration of corticosteroid 
pulse therapy. CSF samples were also collected 
from 10 patients with IND (6 women, 4 men; mean 
age, 39 ± 16 years (range, 18–57 years)). IND 
comprised viral meningitis/encephalitis (n = 8), 
acute disseminated encephalomyelitis (n = 1) or 
neuro-Behçet’s disease (n = 1). All 10 patients 
displayed mononuclear pleocytosis (Table 1). As 
control samples, blood samples were collected 
from 10 healthy individuals (4 women, 6 men; 
mean age, 33 ± 9 years (range, 21–52 years)).
Flow Cytometry
Venous blood was collected in heparinized tubes 
and analyzed within 2 h after sampling. CSF cells 
were collected by centrifugation (250 × g for 10 min) 
and resuspended in PBS with 1% BSA. Whole 
blood and CSF cells ( 5 × 10
3 cells/test) were 
labeled with directly conjugated monoclonal anti-
bodies, according to the instructions of the manu-
facturer, using anti-CD3 PerCP (Becton Dickinson, 
San Jose, CA), anti-CD4 FITC, anti-CD8 FITC 
(Pharmingen, San Diego, CA), anti-CCR4 PE, 
anti-CXCR3 PE (Pharmingen, San Diego, CA) and 
anti-CCR2 PE (Dako, Kyoto, Japan), in addition 
to isotype-speciﬁ  c antibody controls. Cells were 
ﬁ  xed in 2% paraformaldehyde and stored in the 
dark before analysis using a FACS ﬂ  ow cytometer 
(Becton Dickinson). Flow cytometry data were 
processed using CellQuest software (Becton Dick-
inson). Data are reported as percentages of all T 
cells (identiﬁ  ed as CD3
+ cells) staining positively 
for CD4
+CXCR3
+, CD8
+CXCR3
+, CD4
+CCR4
+, 
CD8
+CCR4
+, CD4
+CCR2
+ or CD8
+CCR2
+.
Statistical analysis
Comparisons between expressions of chemokine 
receptors in CSF and blood from MS patients, 
CSF from patients with IND and blood from 
healthy controls were performed by nonparametric 
Mann-Whitney U and Kruskall-Wallis tests. Val-
ues of p   0.05 were considered statistically 
signiﬁ  cant.
Results
Comparison of Th1/Th2-related che-
mokine receptor expression
The percentage of CD4
+ or CD8
+ T cells expressing 
these chemokine receptors among all CD3
+ T cells 
was determined by 3-color ﬂ  ow cytometry using 
anti-CD3 antibody and anti-CD4 antibody or anti-
CD8 antibody and one of the following anti-
chemokine receptor antibodies: anti-CXCR3 
Table 1. Patient demographics and CSF ﬁ  ndings.
  Gender  Age median (range)  CSF WBC (/mm3)  CSF protein
 (M:F)  (years)    (mg/dl)
MS (n = 10) 2:8  44  (20–56)  20  ± 6 53  ± 11
IND (n = 10) 4:6  39  (18–57)  183  ± 112 62  ± 24
Healthy (n = 10) 6:4  33  (21–52)  NA  NA
CSF WBC and protein are presented as mean ±SD.
Abbreviation: CSF: cerebrospinal ﬂ  uid; WBC: white blood cells; MS: multiple sclerosis; IND: other inﬂ  ammatory neurological diseases; NA: 
not applicable.465
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antibody; anti-CCR4 antibody; or anti-CCR2 
antibody. In peripheral blood, percentages of 
CD4
+CXCR3
+ cells were higher for MS patients 
than for healthy controls (p = 0.013; Fig. 1A). 
However, no differences were observed in 
percentages of other subsets (Fig. 1A). When 
comparing CSF and blood in MS patients, 
percentages of all subsets other than CD8
+CXCR3
+ 
cells were signiﬁ  cantly higher in CSF (Fig. 1B). 
Expressions of all chemokine receptors were also 
elevated in CSF from IND patients compared 
levels in blood for healthy controls (Fig. 1C). 
However, no differences were observed between 
percentages of CD4
+CXCR3
+, CD8
+CXCR3
+, 
CD4
+CCR4
+ or CD8
+CCR4
+ cells between groups 
(Fig. 1C). These ﬁ  ndings suggest that activated T 
lymphocytes cross the blood-brain barrier (BBB) 
and contribute to inﬂ  ammatory response in the 
pathogenesis of MS.
Comparison of CD4
+CXCR3
+/
CD4
+CCR4
+ ratios
As CXCR3 is expressed on Th1 cells and CCR4 is 
expressed on Th2 cells, CD4
+CXCR3
+/CD4
+CCR4
+ 
ratio represents Th1/Th2 balance. CD4
+CXCR3
+/
CD4
+CCR4
+ ratio in blood was signiﬁ  cantly higher 
for MS patients than for healthy controls (p = 0.034). 
In MS patients, CD4
+CXCR3
+/CD4
+CCR4
+ ratio 
was similar between CSF and blood. However, 
CD4
+CXCR3
+/CD4
+CCR4
+ ratio in CSF was 
signiﬁ  cantly lower for IND patients than for MS 
patients (p = 0.042; Fig. 2). These ﬁ  ndings suggest 
that Th1/Th2 imbalance indicates the pathological 
nature of MS.
Comparison of CCR2 expression
When comparing CSF and blood in MS patients, 
percentages of CD4
+CCR2
+ and CD8
+CCR2
+ cells 
Figure 1. Comparison of chemokine receptor expression on blood T cells between MS and healthy controls (A), on T cells between CSF 
and blood from MS (B), and on CSF T cells between MS and IND (C). Data are shown as percentages of all T cells staining positive for 
CD4
+CXCR3
+, CD8
+CXCR3
+, CD4
+CCR4
+ or CD8
+CCR4
+.466
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were signiﬁ  cantly increased in CSF (p = 0.002 and 
0.014, respectively; Fig. 3). In CSF, CCR2 expres-
sion on CSF CD4
+ and CD8
+ cells was also higher 
for MS patients than for IND patients (p = 0.023 
and 0.028, respectively; Fig. 3). CCR2 expression 
was highest in CSF from MS patients (Fig. 3). These 
ﬁ  ndings suggest that CCR2-expressing T cells play 
a pivotal role in the pathogenesis of MS.
Discussion
Recruitment of autoreactive T lymphocytes from 
blood to the CNS plays a crucial role in the 
pathogenesis of MS, as this process initiates the 
inﬂ  ammatory response leading to demyelination 
and axonal degeneration. Interactions between 
chemokines and chemokine receptors are thought 
to be important in the activation and migration 
of activated T lymphocytes across the BBB. 
Investigation of chemokine receptor expression on 
T cells in the blood and CSF of MS patients is thus 
key to understanding the pathogenic processes in 
MS. In the present study, percentages of CXCR3-, 
CCR4- and CCR2-expressing T cells were higher 
in CSF than in blood, and this characteristic was 
more pronounced in CD4 T cells than in CD8 T 
cells. These findings suggest that activated T 
lymphocytes, including myelin-reactive CD4
+ T 
cells, cross the BBB and contribute to the 
inﬂ  ammatory response (Fig. 1). No differences in 
percentages of CXCR3-expressing CD8
+ T cells 
were identiﬁ  ed in this study between CSF and blood 
from MS patients. Previously, a signiﬁ  cant increase 
in percentage of CXCR3-expressing CD8
+ T cells 
was found in CSF compared to blood from MS 
patients [Misu et al. 2001]. In the present study, 
expression of chemokine receptors was measured 
using 3-color ﬂ  ow cytometry. Expressions of each 
chemokine on CD4
+ and CD8
+ T cells are shown 
as percentages of all T cells. Since our results 
demonstrated a greatly increased percentage of 
CXCR3-expressing CD4
+ T cells in CSF from MS 
patients, the percentage of CXCR3-expressing 
CD8
+ T cells in CSF was relatively low, as in blood. 
Technical approaches to the detection of chemokine 
receptors by FACS analysis strongly affect the 
results [Kivisakk et al. 2002].
No difference in CD4
+CXCR3
+/CD4
+CCR4
+ 
ratio was seen between CSF and blood from MS 
patients (Fig. 2). Previous studies comparing blood 
from MS patients and healthy individuals have 
reported elevations of Th1-type chemokine receptor 
CXCR3 and CCR5 expression and reductions in 
the expression of Th2-type chemokine receptors 
CCR4 and CCR3 in patients with MS [Misu et al. 
2001; Nakajima et al. 2004; Sorensen et al. 1999]. 
Those ﬁ  ndings suggest that Th1 predominance in 
the blood and CSF is involved in the pathogenesis 
of MS. Our study shows that activated T cells 
expressing chemokine receptors invade the CNS 
of IND patients, as seen in MS patients. However, 
CD4
+CXCR3
+/CD4
+CCR4
+ ratio in the CSF was 
signiﬁ  cantly higher for MS patients than for IND 
patients (Fig. 2). Th1/Th2 imbalance may thus 
reﬂ  ect the pathological nature of MS and indicate 
the degree of CNS inﬂ  ammation.
Figure 2. Comparison of CD4
+CXCR3
+/CD4
+CCR4
+ between CSF and blood from MS patients, CSF from patients with IND, and blood from 
healthy controls. As CD4
+CXCR3
+ cells are Th1 cells and CD4
+CCR4
+ cells are Th2 cells, CD4
+CXCR3
+/CD4
+CCR4
+ ratio represents Th1/
Th2 balance.467
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Our previous study showed that expressions of 
CCR2 and CD14 on monocytes in the blood of MS 
patients are markedly decreased, and revealed a 
significant negative correlation between 
CD4
+CXCR3
+/CD4
+CCR4
+ ratio and CCR2 and 
CD14 expressions on monocytes [Nakajima et al. 
2004b]. To elucidate whether decreases in percent-
age of CD14
+CCR2
+ monocytes in blood corre-
sponded to those in CSF, the present study 
investigated CCR2-expressing monocytes in the 
CSF of MS patients. No CD14
+CCR2
+ monocytes 
were detected in the CSF of patients. However, the 
percentage of CCR2-expressing T cells was 
markedly increased in the CSF of MS patients. The 
percentage of these cells among blood T cells was 
extremely low. Although CCR2-expressing T cells 
were detectable in CSF from patients with IND, 
CCR2 expression was clearly decreased compared 
to MS patients (Fig. 1C). CCL2 and CCR2 are 
thought to play pivotal roles in the development 
and relapse of MS and EAE. However, the immune 
cascade, including CCL2 and CCR2, in the CNS 
is poorly understood. CCL2 and CCR2 expressions 
in the brain are closely associated with disease 
activity in EAE [Jee et al. 2002]. CCL-knockout 
mice are resistant to EAE and show signiﬁ  cant 
reductions in CNS macrophage invasion [Huang 
et al. 2001]. Although T cells from CCL2 knockout 
mice transfer EAE to wild-type mice, wild-type T 
cells fail to cause clinical EAE in CCL-knockout 
mice [Huang et al. 2001]. CCR2-knockout mice 
likewise display decreased susceptibility to EAE 
[Fife et al. 2000; Izikson et al. 2000]. T cells from 
CCR2 knockout mice are able to induce EAE in 
wild-type mice, whereas CCR2-knockout recipients 
of wild-type T cells fail to develop EAE [Fife et al. 
2000]. These ﬁ  ndings suggest that CCL2/CCR2-
induced macrophage recruitment is critical in the 
pathogenesis of EAE. CCL2 and CCR2 are abun-
dantly detected in plaque lesions of MS patients 
[Mahad and Ransohoff, 2003; McManus et al. 
1998]. An increased number of intrathecal CCR2-
expressing T cells was also demonstrated in the 
present study. These cells may thus play a patho-
genic role in acute lesions of MS.
Recent studies have shown that CCL2 concen-
trations in CSF and serum from early active MS 
patients are reduced, but increase during remission 
[Bartosik-Psujek and Stelmasiak, 2005; Mahad 
et al. 2002; Nakajima et al. 2004a; Sorensen et al. 
1999, 2001, 2004]. Reduced CCL2 levels have also 
been seen in clinical isolated syndrome [Sorensen 
et al. 1999]. In contrast, elevated levels of CCL2 
are present in viral meningitis and CNS vasculitis 
[Mahad et al. 2002] and in HIV-associated demen-
tia [Franciotta et al. 2001]. This reduced CCL2 
expression is a key to elucidating the pathogenesis 
of MS. As a mechanism for the low CCL2 levels 
in CSF, Mahad et al. suggested that CCL2 was 
consumed by circulating CCR2-expressing mono-
nuclear cells, and that CCR2 was downregulated 
on cells migrating in response to CCL2 via the in 
vitro BBB model [Mahad et al. 2006]. In the pres-
ent study, CCR2-expressing monocytes were not 
detected in CSF. This downregulation of CCR2 on 
monocytes in CSF would be due to internalization 
of CCR2 following binding of CCL2 during trans-
migration to the CSF. Conversely, percentages of 
Figure 3. Comparison of CCR2 expression on CD4
+ and CD8
+ T cells between CSF and blood from MS patients, CSF from patients with 
IND, and blood from healthy controls. Data are shown as percentages of all T cells staining positive for CD4
+CCR2
+or CD8
+CCR2
+.468
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CCR2-expressing T cells were elevated in CSF of 
MS patients. Since a large amount of CCR2-
expressing T cells are thought to transmigrate to 
the CSF in MS, these cells would be detected even 
after consumption of CCL2. Increases in numbers 
of CCR2-expressing T cells in CSF are thought to 
be characteristic for MS, and these cells may be 
associated with the relapsing-remitting autoim-
mune reactions of MS.
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